LEXICON PHARMACEUTICALS, INC. Treasury Stock, Value, Acquired, Cost Method
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- LEXICON PHARMACEUTICALS, INC. treasury stock, value, acquired, cost method for the quarter ending 2024-03-31 was $1.73M, a 109.95% increase year-over-year.
- LEXICON PHARMACEUTICALS, INC. treasury stock, value, acquired, cost method for the quarter ending 2023-03-31 was $824.00K, a 4.63% decline year-over-year.
- LEXICON PHARMACEUTICALS, INC. treasury stock, value, acquired, cost method for the quarter ending 2022-03-31 was $864.00K, a 67.70% decline year-over-year.
- LEXICON PHARMACEUTICALS, INC. treasury stock, value, acquired, cost method for the quarter ending 2021-03-31 was $2.67M, a 189.82% increase year-over-year.
- LEXICON PHARMACEUTICALS, INC. treasury stock, value, acquired, cost method for fiscal 2024 was $1.73M, a 109.95% increase from fiscal 2023.
- LEXICON PHARMACEUTICALS, INC. treasury stock, value, acquired, cost method for fiscal 2023 was $824.00K, a 4.63% decline from fiscal 2022.
- LEXICON PHARMACEUTICALS, INC. treasury stock, value, acquired, cost method for fiscal 2022 was $864.00K, a 67.70% decline from fiscal 2021.
- LEXICON PHARMACEUTICALS, INC. treasury stock, value, acquired, cost method for fiscal 2021 was $2.67M, a 160.72% increase from fiscal 2020.
| Period end | Treasury Stock, Value, Acquired, Cost Method 3 month | Treasury Stock, Value, Acquired, Cost Method 12 month |
|---|---|---|
| 2024-12-31 | $1.73M 10-K · filed 2025-03-07 | |
| 2024-03-31 | $1.73M 10-Q · filed 2024-11-13 | |
| 2023-12-31 | $824.00K 10-K · filed 2025-03-07 | |
| 2023-03-31 | $824.00K 10-Q · filed 2024-11-13 | |
| 2022-12-31 | $864.00K 10-K · filed 2025-03-07 | |
| 2022-03-31 | $864.00K 10-Q · filed 2023-11-08 | |
| 2021-12-31 | $2.67M 10-K · filed 2024-03-25 | |
| 2021-03-31 | $2.67M 10-Q · filed 2022-11-09 | |
| 2020-12-31 | $1.03M 10-K · filed 2023-03-03 | |
| 2020-06-30 | $103.00K 10-Q · filed 2021-11-09 | |
| 2020-03-31 | $923.00K 10-Q · filed 2021-11-09 | |
| 2019-12-31 | $941.00K 10-K · filed 2022-03-10 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-11-07 | $941.00K derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-03-31 | $941.00K 10-Q · filed 2020-10-30 | $941.00K derived: sum of 4 quarters · filed 2021-03-12 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $972.00K 10-K · filed 2021-03-12 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $972.00K derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-11-07 | $972.00K derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-03-31 | $972.00K 10-Q · filed 2019-08-01 | $972.00K derived: sum of 4 quarters · filed 2020-03-12 |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $1.68M 10-K · filed 2020-03-12 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $1.68M derived: sum of 4 quarters · filed 2019-03-15 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-30 | $1.68M derived: sum of 4 quarters · filed 2019-03-15 |
| 2017-03-31 | $1.68M 10-Q · filed 2018-05-03 | $1.68M derived: sum of 4 quarters · filed 2019-03-15 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-15 | $621.00K 10-K · filed 2019-03-15 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $621.00K derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-01 | $621.00K derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-03-31 | $621.00K 10-Q · filed 2017-05-04 | $621.00K derived: sum of 4 quarters · filed 2018-03-01 |
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $357.00K 10-K · filed 2018-03-01 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | -$1.42M derived: sum of 4 quarters · filed 2017-03-06 |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | -$1.42M derived: sum of 4 quarters · filed 2017-03-06 |
| 2015-03-31 | $357.00K 10-Q · filed 2016-05-05 | -$1.42M derived: sum of 4 quarters · filed 2017-03-06 |
| 2014-12-31 | -$1.77M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-06 | -$887.00K 10-K · filed 2017-03-06 |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | -$859.00K derived: sum of 4 quarters · filed 2016-03-11 |
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | -$859.00K derived: sum of 4 quarters · filed 2016-03-11 |
| 2014-03-31 | $887.00K 10-Q · filed 2015-05-05 | -$859.00K derived: sum of 4 quarters · filed 2016-03-11 |
| 2013-12-31 | -$1.75M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-11 | -$873.00K 10-K · filed 2016-03-11 |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $303.00K derived: sum of 4 quarters · filed 2015-03-12 |
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $303.00K derived: sum of 4 quarters · filed 2015-03-12 |
| 2013-03-31 | $873.00K 10-Q · filed 2014-05-08 | $303.00K derived: sum of 4 quarters · filed 2015-03-12 |
| 2012-12-31 | -$570.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | -$285.00K 10-K · filed 2015-03-12 |
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | $69.00K derived: sum of 4 quarters · filed 2014-03-07 |
| 2012-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-01 | $69.00K derived: sum of 4 quarters · filed 2014-03-07 |
| 2012-03-31 | $285.00K 10-Q · filed 2013-05-10 | $285.00K derived: sum of 4 quarters · filed 2014-03-07 |
| 2011-12-31 | -$216.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-07 | -$108.00K 10-K · filed 2014-03-07 |
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | $108.00K derived: sum of 4 quarters · filed 2013-03-11 |
| 2011-06-30 | $216.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-02 | $108.00K derived: sum of 4 quarters · filed 2013-03-11 |
| 2011-03-31 | -$108.00K 10-Q · filed 2012-05-03 | |
| 2010-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-11 | -$149.00K 10-K · filed 2013-03-11 |
| 2010-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-01 | |
| 2009-12-31 | -$88.00K 10-K · filed 2012-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |